TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38582538

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments, structural and functional MRI, and electroencephalography in patients with UFS
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients with UFS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multimodal machine-learning model
Number of subjects: 200
Study: 38582540

Group type: EXPERIMENTAL
Intervention: Adebrelimab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (chemotherapy only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scenario and exploratory analyses
Number of subjects: 0
Study: 38582650

Group type: EXPERIMENTAL
Intervention: Olaparib plus abiraterone (300 mg bid + 1000 mg od)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo plus abiraterone (placebo + 1000 mg od)
Number of subjects: 126
Study: 38582713

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab (L + P)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 253
Study: 38582758

Group type: EXPERIMENTAL
Intervention: hEDS patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: hEDS patients during cognitive task
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 38582863

Group type: EXPERIMENTAL
Intervention: Propolis mouthwash
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 45
Study: 38582874

Group type: EXPERIMENTAL
Intervention: Active TENS (modulating frequency of 2-125 Hz, maximal tolerable intensity for 30 min)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo TENS (current delivered for 45 s, ramping to 0 in the last 15 s)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 34
Study: 38582934

Group type: EXPERIMENTAL
Intervention: Robotic-assisted early mobilization (20 min, twice daily during the first week in ICU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional mobilization (retrospective control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Robotic-assisted early mobilization
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional mobilization
Number of subjects: 29
Study: 38582974

Group type: EXPERIMENTAL
Intervention: Ultra-low-temperature cryoablation
Number of subjects: 64
Study: 38583084

Group type: EXPERIMENTAL
Intervention: Behaviorally designed gamification
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Loss-framed financial incentives
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Gamification + financial incentives
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1062
Study: 38583086

Group type: EXPERIMENTAL
Intervention: CABG guided by CCTA
Number of subjects: 114
Study: 38583091

Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine
Number of subjects: 5260

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent inactivated influenza vaccine
Number of subjects: 5260
Study: 38583092

Group type: EXPERIMENTAL
Intervention: Plozasiran (10, 25, or 50 mg)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 38583146

Group type: EXPERIMENTAL
Intervention: Simultaneous virtual patient education with concurrent prescription of SGLT2i or GLP1-RA
Number of subjects: 200

Group type: COMPARATOR
Intervention: Education-First (2 months of virtual education followed by medication prescription)
Number of subjects: 200
Study: 38583147

Group type: EXPERIMENTAL
Intervention: Routine PRO assessment (KCCQ-12 completed at each visit, results shared with clinician)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Usual care (KCCQ-12 completed at randomization and 1 year later, not shared with clinician)
Number of subjects: 1248
Study: 38583174

Group type: EXPERIMENTAL
Intervention: Coronary Slow Flow (CSF) present in 23 participants (22.1%)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Invasive coronary function testing measuring CFR and IMR
Number of subjects: 104

Group type: COMPARATOR
Intervention: Invasive diagnosis of CMD
Number of subjects: 104
Study: 38583185

Group type: EXPERIMENTAL
Intervention: Telephone-based telehealth model for guideline-directed medical therapy initiation and titration.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 103
Study: 38583289

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously every 4 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 41
Study: 38583316

Group type: EXPERIMENTAL
Intervention: Non-hormonal pessary applied once daily for the first 7 days and twice a week for the subsequent 31 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Non-hormonal pessary
Number of subjects: 79
Study: 38583450

Group type: COMPARATOR
Intervention: Stable-dose conventional synthetic DMARDs (n=80)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Half-dose conventional synthetic DMARDs (n=42)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Half-dose conventional synthetic DMARDs tapering to withdrawal (n=38)
Number of subjects: 160
Study: 38583455

Group type: EXPERIMENTAL
Intervention: Remission induction with high-dose cytarabine (3 g/m²)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Disease control (watchful waiting before allogeneic HSCT)
Number of subjects: 281
Study: 38583461

Group type: EXPERIMENTAL
Intervention: Incentive vouchers for attending motivational interviewing sessions and timely appointments at government ART clinics; equivalent to 14 days' wages over 12 months.
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 2314
Study: 38583491

Group type: EXPERIMENTAL
Intervention: JNJ-3989 (200 mg subcutaneously every 4 weeks) + JNJ-6379 (250 mg oral daily) + NA (oral daily)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: JNJ-3989 + JNJ-6379 + NA
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo for JNJ-3989 and JNJ-6379 + active NA
Number of subjects: 130
Study: 38583540

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg/day for 4 weeks starting on the third day after RFA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (historical control, RFA without oral steroids)
Number of subjects: 48
Study: 38583574

Group type: EXPERIMENTAL
Intervention: Adjuvant-RT
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Salvage-RT
Number of subjects: 1396
Study: 38583715

Group type: EXPERIMENTAL
Intervention: Scheduled analgesia (paracetamol 1 g + ibuprofen 400 mg every 6 hours for the first 24 hours postpartum)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Scheduled analgesia
Number of subjects: 200

Group type: COMPARATOR
Intervention: On-demand analgesia
Number of subjects: 200
Study: 38583720

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy and local treatment of metastases
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Maintenance therapy after radiotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single organ metastasis
Number of subjects: 51
Study: 38583802

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 38584058

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 + FMP1/AS02 (same site)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 + FMP1/AS02 (separate sites)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RTS,S-containing regimen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FMP1/AS02 alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 + FMP1/AS02
Number of subjects: 60

Group type: COMPARATOR
Intervention: FMP1/AS02
Number of subjects: 60
Study: 38584159

Group type: EXPERIMENTAL
Intervention: Quadpill (candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Candesartan 8 mg
Number of subjects: 62
Study: 38584166

Group type: EXPERIMENTAL
Intervention: Personalized therapeutic cancer vaccine (PTCV) GNOS-PV02 coadministered with plasmid-encoded interleukin-12 plus pembrolizumab
Number of subjects: 36
Study: 38584200

Group type: EXPERIMENTAL
Intervention: MAKASI intervention
Number of subjects: 821
Study: 38584244

Group type: EXPERIMENTAL
Intervention: PDDD (posterior dynamic distraction device)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: PDDD
Number of subjects: 7
Study: 38584394

Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia ablation (VTA)
Number of subjects: 211
Study: 38584600

Group type: EXPERIMENTAL
Intervention: Fuke Qianjin capsule, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 38584921

Group type: EXPERIMENTAL
Intervention: DigiRehab platform (personalized training)
Number of subjects: 50
Study: 38585154

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence as a Medical Device (AIaMD)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 622
Study: 38585206

Group type: EXPERIMENTAL
Intervention: TAR-200 treatment (two 7-day or two 21-day dosing cycles)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TAR-200 treatment
Number of subjects: 12
Study: 38585593

Group type: EXPERIMENTAL
Intervention: MV140 (3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (6 months)
Number of subjects: 0
Study: 38585592

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) for renal tumors
Number of subjects: 8566
Study: 38585728

Group type: EXPERIMENTAL
Intervention: Opioid use during pregnancy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Public insurance
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Housing instability
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Three or more adverse childhood experiences
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Physical or emotional abuse during pregnancy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Food insecurity during pregnancy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Food insecurity during pregnancy (after controlling for demographic characteristics)
Number of subjects: 254
Study: 38585865

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 12 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 62
Study: 38586018

Group type: EXPERIMENTAL
Intervention: Intestinal energy harvest post-MBS
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intestinal energy harvest
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Calorie absorption assessment
Number of subjects: 67
Study: 38586120

Group type: EXPERIMENTAL
Intervention: Test formulation of megestrol acetate (625 mg/5 mL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Reference formulation of megestrol acetate (625 mg/5 mL)
Number of subjects: 54
Study: 38586170

Group type: EXPERIMENTAL
Intervention: Group A (1× IFU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (4× IFU)
Number of subjects: 30
Study: 38586278

Group type: EXPERIMENTAL
Intervention: Mandatory twice-weekly evaluations
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard of care weekly clinical evaluations with ad hoc supplemental evaluations
Number of subjects: 305
Study: 38586292

Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Families (MCT-F)
Number of subjects: 48
Study: 38586431

Group type: EXPERIMENTAL
Intervention: Adenosine stress 1.5 T cardiovascular magnetic resonance imaging (CMR) imaging and invasive coronary reactivity testing
Number of subjects: 118
Study: 38586479

Group type: EXPERIMENTAL
Intervention: High-dose RBT-1 (90 mg SnPP/240 mg FeS)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low-dose RBT-1 (45 mg SnPP/240 mg FeS)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: High-dose RBT-1
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low-dose RBT-1
Number of subjects: 135
Study: 38586588

Group type: EXPERIMENTAL
Intervention: Original health system intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Simplified intervention at control sites
Number of subjects: 16
Study: 38586589

Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 200

Group type: COMPARATOR
Intervention: Td
Number of subjects: 200
Study: 38587033

Group type: EXPERIMENTAL
Intervention: LP-PRP injection during surgery (5-mL dose)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Double-row suture-bridge ARCR alone
Number of subjects: 96
Study: 38587056

Group type: EXPERIMENTAL
Intervention: Self-management neuro-rehabilitation intervention (6-8 sessions lasting 45-60 minutes over 9 months)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Self-management neuro-rehabilitation intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 69
Study: 38587079

Group type: EXPERIMENTAL
Intervention: 10E8VLS (5 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10E8VLS and VRC07-523LS (5 mg/kg each)
Number of subjects: 8
Study: 38587119

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fortifier (CF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both BC and CF
Number of subjects: 0
Study: 38587233

Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg once weekly)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 38587237

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 6522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6522
Study: 38587239

Group type: EXPERIMENTAL
Intervention: Microaxial flow pump (Impella CP) plus standard care
Number of subjects: 355

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 355
Study: 38587247

Group type: EXPERIMENTAL
Intervention: 80-mg olezarsen
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 50-mg olezarsen
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pooled olezarsen groups
Number of subjects: 66
Study: 38587241

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment (metoprolol or bisoprolol)
Number of subjects: 5020

Group type: COMPARATOR
Intervention: No beta-blocker treatment
Number of subjects: 5020
Study: 38587249

Group type: EXPERIMENTAL
Intervention: 50-mg olezarsen
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 80-mg olezarsen
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 38587254

Group type: EXPERIMENTAL
Intervention: CSL112 (6 g, four weekly infusions)
Number of subjects: 18219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18219

Group type: EXPERIMENTAL
Intervention: CSL112
Number of subjects: 18219
Study: 38587261

Group type: EXPERIMENTAL
Intervention: Self-expanding valve
Number of subjects: 716

Group type: COMPARATOR
Intervention: Balloon-expandable valve
Number of subjects: 716
Study: 38587276

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (E2) gel + ADT
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 310

Group type: COMPARATOR
Intervention: ADT-only control arm
Number of subjects: 310
Study: 38587329

Group type: EXPERIMENTAL
Intervention: Customizable sequential digital cognitive aid (DCA) with ILCOR algorithm poster displayed on the wall
Number of subjects: 108

Group type: COMPARATOR
Intervention: Poster cognitive aid (standard of care [SOC])
Number of subjects: 108
Study: 38587333

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 3242

Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (control)
Number of subjects: 3242
Study: 38587380

Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine FDC (50 mg dolutegravir and 300 mg lamivudine)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine FDC
Number of subjects: 362
Study: 38587557

Group type: EXPERIMENTAL
Intervention: Alcohol-mediated renal denervation (RDN)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 301
Study: 38587645

Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine hydrochloride 9 mg/kg (i.v.) followed by 3 mg/kg infusion via minipump
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine hydrochloride 32 mg/kg oral administration
Number of subjects: 0
Study: 38587643

Group type: EXPERIMENTAL
Intervention: trastuzumab-pertuzumab and chemotherapy de-escalation
Number of subjects: 500

Group type: COMPARATOR
Intervention: PET[-] patients with SUVmax < 2.5
Number of subjects: 500
Study: 38587752

Group type: EXPERIMENTAL
Intervention: Post-COVID syndrome (PCS) score applied at 3 and 12 months after diagnosis.
Number of subjects: 603
Study: 38587822

Group type: EXPERIMENTAL
Intervention: Zerlasiran 300 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zerlasiran 600 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zerlasiran 200 mg (two doses)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zerlasiran 300 mg (two doses)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zerlasiran 450 mg (two doses)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 37
Study: 38587827

Group type: EXPERIMENTAL
Intervention: ABI plus 3 months of mobile chat-based instant messaging support
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: ABI plus 3 months of mobile chat-based instant messaging support (adjusted for baseline characteristics)
Number of subjects: 772
Study: 38587846

Group type: EXPERIMENTAL
Intervention: Intravesical interferon
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 52
Study: 38587852

Group type: EXPERIMENTAL
Intervention: Naked-eye 3-dimensional vision training (NVT) for 20 minutes daily
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (no vision training)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Comparison between NVT and control
Number of subjects: 263
Study: 38587881

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy plus self-monitoring (including completion of the 'in-Session Patient Affective Reactions Questionnaire' and the 'Rift In-Session Questionnaire' for 10 weeks)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Individual psychotherapy (treatment as usual, no postsession questionnaires)
Number of subjects: 475
Study: 38587921

Group type: EXPERIMENTAL
Intervention: HSM (10 running-based HIIT sessions, 5 × 4 min at 90%-95% maximal heart rate)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HSM + LIT (same as HSM with additional 30 min of LIT after each HIIT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: CG (regular training)
Number of subjects: 33
Study: 38587995

Group type: EXPERIMENTAL
Intervention: FFR-guided complete revascularization
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Culprit-lesion-only PCI
Number of subjects: 1542
Study: 38588025

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 1414

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1414
Study: 38588408

Group type: EXPERIMENTAL
Intervention: XRD-0394
Number of subjects: 0
Study: 38588450

Group type: EXPERIMENTAL
Intervention: Home haemodialysis (HHD)
Number of subjects: 58984
Study: 38588457

Group type: EXPERIMENTAL
Intervention: Dance
Number of subjects: 7837

Group type: EXPERIMENTAL
Intervention: Gait/balance/functional training
Number of subjects: 7837

Group type: EXPERIMENTAL
Intervention: Multi-domain training
Number of subjects: 7837

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 7837

Group type: EXPERIMENTAL
Intervention: Aqua-based training
Number of subjects: 7837

Group type: EXPERIMENTAL
Intervention: Strength/resistance training
Number of subjects: 7837

Group type: EXPERIMENTAL
Intervention: Mind-body training
Number of subjects: 7837

Group type: EXPERIMENTAL
Intervention: Gaming
Number of subjects: 7837

Group type: EXPERIMENTAL
Intervention: Flexibility training
Number of subjects: 7837

Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 7837
Study: 38588480

Group type: EXPERIMENTAL
Intervention: 1,000 mg methylprednisolone i.v./d plus erythropoietin (33,000 IU/d) for 3 days
Number of subjects: 103

Group type: COMPARATOR
Intervention: 1,000 mg methylprednisolone i.v./d plus placebo (saline solution) for 3 days
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both interventions (methylprednisolone with erythropoietin and placebo)
Number of subjects: 103
Study: 38588529

Group type: EXPERIMENTAL
Intervention: Conventional pacemaker (86.3% of patients)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Biventricular pacemaker (CRT-P) (5% of patients)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (8.5% of patients)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: CRT-D implantation (3% of patients)
Number of subjects: 1500
Study: 38588540

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Neuromuscular Exercise (NEMEX)
Number of subjects: 160
Study: 38588552

Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (One MORE); single session, 2 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; not specified
Number of subjects: 0
Study: 38588588

Group type: EXPERIMENTAL
Intervention: SER-401 + nivolumab
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo arm (placebo antibiotic/placebo microbiome modulation + nivolumab)
Number of subjects: 14
Study: 38588646

Group type: EXPERIMENTAL
Intervention: CBCT-DRRs
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT-DRRs
Number of subjects: 0
Study: 38588682

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2)
Number of subjects: 467